Augurex Life Sciences Corp.

Augurex Life Sciences Corp. Augurex is a clinical diagnostics leader advancing biomarker-driven solutions for the early detection and management of autoimmune diseases.

Augurex is a clinical diagnostics leader advancing biomarker-based tests for autoimmune diseases, enabling earlier, more precise detection and disease management to improve patient outcomes. Our lead products include JOINTstat® (14-3-3eta), which supports the diagnosis and monitoring of rheumatoid arthritis (RA), and SPINEstat™ (Anti-14-3-3eta Multiplex), a first-in-class blood test that aids in t

he diagnosis of axial spondyloarthritis (axSpA) and helps distinguish it from mechanical back pain. By enabling earlier, more precise diagnosis and better disease management, we empower clinicians and patients with the tools to take control of disease and improve long-term outcomes.

Earlier diagnosis changes lives. Augurex is proud to share that three abstracts have been accepted for presentation at t...
07/22/2026

Earlier diagnosis changes lives.

Augurex is proud to share that three abstracts have been accepted for presentation at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Conference in Anaheim, California.

The accepted research highlights the growing clinical utility of both 14-3-3eta autoantibodies and the 14-3-3eta protein in addressing critical diagnostic challenges across autoimmune diseases, including axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA).

We're especially excited that one of our abstracts has been recognized with the ADLM Immunology Abstract Award by the Immunology & Infectious Disease Division.

If you'll be attending ADLM 2026 in Anaheim, we invite you to:

• Visit our posters during the Clinical and Diagnostic Immunology Session on July 29 presented by Dr. Anthony Marotta, PhD

•Stop by Augurex’s kiosk in the ADLM Disruptive Technology Booth July 26-30 to learn more about SPINEstat®, recognized as a finalist for this year's award

Learn more about the accepted Augurex abstracts: https://augurex.com/augurex-to-present-three-abstracts-at-adlm-2026/

We’re very happy to share that our abstract, “Anti-14-3-3eta Autoantibodies: A Novel Diagnostic Biomarker that Discrimin...
07/20/2026

We’re very happy to share that our abstract, “Anti-14-3-3eta Autoantibodies: A Novel Diagnostic Biomarker that Discriminates Axial Spondyloarthritis from Mechanical Back Pain,” has received the Immunology Abstract Award for the Association for Diagnostics & Laboratory Medicine 2026 Conference.

Authored by Dr. Anthony Marotta, PhD, in collaboration with global key opinion leaders, the award-winning research was selected from approximately 800 submissions and has also earned the additional distinction of being selected for presentation during an Immunology & Infectious Disease (IID) Division ePoster Discussion, a highlighted session for top-rated abstracts.

The recognition highlights the potential of SPINEstat® to help reliably distinguish axial spondyloarthritis from mechanical back pain. Dr. Marotta will accept the award on July 27 at the IID Division Awards Reception and present the findings on July 29 from 12:30 - 1:30pm. Augurex will also showcase SPINEstat® at the ADLM Clinical Lab Expo, July 28–30, as a finalist for the ADLM Disruptive Technology Award.

Learn more about the IID Division award: https://myadlm.org/community/scientific-divisions/scientific-division-awards

Augurex has been named a finalist in the ADLM 2026 Disruptive Technology Award competition for SPINEstat® (Anti-14-3-3et...
05/29/2026

Augurex has been named a finalist in the ADLM 2026 Disruptive Technology Award competition for SPINEstat® (Anti-14-3-3eta Multiplex).

Presented by the (Association for Diagnostics and Laboratory Medicine), this highly competitive award program recognizes technologies with the potential to advance laboratory medicine and improve patient care. Advancing from semi-finalist to finalist reflects the scientific merit, clinical relevance, and transformative impact of SPINEstat®, a first-in-class biomarker-based diagnostic test designed to support earlier identification of axial spondyloarthritis (axSpA) and differentiate inflammatory disease from mechanical back pain.

As a finalist, Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, where the winner will be announced, and will showcase SPINEstat® at the ADLM Clinical Lab Expo July 28-30.

We are grateful for the recognition from ADLM and congratulate all finalists selected this year. Stay tuned!

Learn more about SPINEstat®: https://augurex.com/axial-spondyloarthritis/

Learn more about the award: https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestants

May 20 marks , highlighting conditions where the immune system drives inflammation, pain, and joint damage.These diseas...
05/20/2026

May 20 marks , highlighting conditions where the immune system drives inflammation, pain, and joint damage.

These diseases are complex, and early diagnosis is not always straightforward.

Better insight into underlying disease biology can help bring clarity earlier.

At Augurex, we are advancing biomarker approaches such as JOINTstat® (14-3-3eta) for rheumatoid arthritis and SPINEstat® (anti-14-3-3eta Multiplex) for axial spondyloarthritis to support more informed clinical decisions across and autoimmune disease care.

May is , a reminder that arthritis is more than joint pain. It is a progressive disease that can lead to irreversible d...
05/04/2026

May is , a reminder that arthritis is more than joint pain. It is a progressive disease that can lead to irreversible damage and loss of function if not identified and managed early.

Earlier insight matters.

At Augurex, solutions like JOINTstat® (14-3-3eta) and SPINEstat® (anti-14-3-3eta Multiplex) are helping bring greater clarity to disease risk and support more informed clinical decisions in and better patient management.

May 2nd is , focused on ankylosing spondylitis, a form of axial spondyloarthritis that can lead to debilitating spinal ...
05/02/2026

May 2nd is , focused on ankylosing spondylitis, a form of axial spondyloarthritis that can lead to debilitating spinal mobility issues.

It often begins in early adulthood with persistent back pain, stiffness, and fatigue, yet diagnosis can take 7 to 10 years.

Many patients are initially told their symptoms are mechanical, while underlying inflammatory disease continues to progress.

Raising awareness of ankylosing spondylitis and the broader spectrum is critical, but improving how these conditions are recognized earlier is what ultimately changes outcomes in patient care.

As part of , there is growing recognition that these diseases are often under-identified in routine care.Many patients ...
05/02/2026

As part of , there is growing recognition that these diseases are often under-identified in routine care.

Many patients experience prolonged and uncertain journeys before reaching the right diagnosis, delaying access to appropriate treatment.

At Augurex, we are advancing diagnostic solutions like SPINEstat® (anti-14-3-3eta Multiplex) are designed to bring greater clarity to inflammatory disease, helping support earlier identification and more confident clinical decision-making across to improve patient outcomes.

Augurex will be attending the Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting, May 14 - 1...
04/29/2026

Augurex will be attending the Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting, May 14 - 16 in Toronto.

SPARTAN brings together leading rheumatologists dedicated to advancing research and care in axial spondyloarthritis (axSpA). We’re proud to engage with and support this community with SPINEstat®, a first-in-class diagnostic test designed to enable earlier identification of axSpA and differentiate it from mechanical back pain.

If you’re attending and would like to connect, please reach out to Chahal to coordinate a meeting during the conference.

Looking forward to engaging discussions and new connections. Let’s connect at SPARTAN 2026.

Read more in our press release: https://augurex.com/augurex-to-attend-spartan-2026-annual-meeting/

Augurex will be attending the Northwest Rheumatism Society Annual Meeting, taking place April 30 – May 2, 2026 in Vancou...
04/22/2026

Augurex will be attending the Northwest Rheumatism Society Annual Meeting, taking place April 30 – May 2, 2026 in Vancouver, Canada.We look forward to connecting with rheumatology clinicians and researchers from across the Pacific Northwest to discuss advances in inflammatory arthritis and the role of biomarker-driven diagnostics in supporting earlier and more informed care decisions.

If you’re attending the meeting, we’d welcome the opportunity to connect. Please reach out directly to Klompas or Bleakley to coordinate a time during the conference.

Learn more about the meeting: https://nwrsmeeting.org/

Augurex will be attending and exhibiting at the Congress of Clinical Rheumatology (CCR) East 2026, April 30 - May 3 in D...
04/16/2026

Augurex will be attending and exhibiting at the Congress of Clinical Rheumatology (CCR) East 2026, April 30 - May 3 in Destin, FL.

Visit us at Booth 64 to learn more about our biomarker-driven diagnostic solutions designed to support earlier identification, risk stratification, and more confident care decisions in inflammatory arthritis.

Our diagnostic solutions include:

• JOINTstat® (14-3-3eta): A modifiable biomarker for diagnosis, prognosis, and monitoring of rheumatoid arthritis.

• SPINEstat® (Anti-14-3-3eta Multiplex): a first-in-class test to aid in the diagnosis of axial spondyloarthritis and help differentiate from mechanical back pain.

We look forward to engaging with community rheumatology providers and discussing how biomarker-based tools can complement clinical assessment and existing laboratory markers.

If you’re attending CCR East, stop by our booth or reach out to Mazinani to schedule time to connect.

Read more: https://augurex.com/augurex-to-exhibit-at-ccr-east-2026/

Address

887 Great Northern Way, Suite 220
Vancouver, BC
V5T4T5

Telephone

+16046373280

Website

Alerts

Be the first to know and let us send you an email when Augurex Life Sciences Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Augurex Life Sciences Corp.:

Shortcuts

Share

Category